ISFM Consensus Guidelines on the Diagnosis and Management of Feline Chronic Kidney Disease

Sparkes, Andy; Caney, Sarah; Chalhoub, Serge; Elliott, Jonathan; Finch, Natalie; Gajanayake, Isuru; Langston, Catherine E.; Lefebvre, Henri; White, Joanna; Quimby, Jessica M.

doi:10.1177/1098612x16631234

Cited by 126 publications

(197 citation statements)

References 192 publications

Supporting

Mentioning

157

Contrasting

Unclassified

Order By: Relevance

“…Renal function seemed to be maintained without improvement, although BPS treatment significantly increased the appetite to a normal level. Dysorexia in cats with CKD can be caused by a stimulation of the chemoreceptor trigger zone by uremic toxins . Recent reports have stated that BPS treatment decreased uremic toxins in a rat model of glomerulonephritis and in human patients .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A Double‐blind, Placebo‐controlled, Multicenter, Prospective, Randomized Study of Beraprost Sodium Treatment for Cats with Chronic Kidney Disease

Takenaka¹,

Iio

Sato

et al. 2017

Veterinary Internal Medicne

View full text Add to dashboard Cite

BackgroundChronic kidney disease (CKD) is a common progressive and irreversible disease in cats. The efficacy and safety of beraprost sodium (BPS) in cats with CKD have not been evaluated.Hypothesis/ObjectivesTo evaluate the efficacy and safety of BPS in the treatment of cats with CKD, as compared to placebo.AnimalsSeventy‐four client‐owned cats with naturally occurring CKD.MethodsDouble‐blind, placebo‐controlled, multicenter, prospective, randomized trial. The cats received BPS (55 μg/cat) or a placebo PO q12 h for 180 days. The primary endpoint was prospectively defined as a change in the serum creatinine (sCr), serum phosphorus‐to‐calcium ratio or urine specific gravity (USG).ResultsThe sCr increased significantly (P = 0.0030) in the placebo group (mean ± SD: 2.8 ± 0.7 to 3.2 ± 1.3 mg/dL) but not in the BPS group (2.4 ± 0.7 to 2.5 ± 0.7 mg/dL). The difference between the groups at day 180 was significant (0.8 mg/dL, 95% CI: 0.2 to 1.3 mg/dL, P = 0.0071). The serum phosphorus‐to‐calcium ratio was significantly (P = 0.0037) increased in the placebo group (0.46 ± 0.10 to 0.52 ± 0.21 mg/dL) but not in the BPS group (0.50 ± 0.08 to 0.51 ± 0.11 mg/dL). There was no significant change in the USG in either group. An adverse event judged as being treatment‐related included vomiting that occurred in 1 case in the placebo group. No clinically relevant change was observed in the CBC and other blood chemistry tests.Conclusions and Clinical ImportanceBeraprost sodium treatment was well tolerated and safe in cats with CKD. BPS inhibited the reduction in renal filtration function as measured by sCr increase.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Chronic kidney disease (CKD) is a progressive and irreversible disease defined as functional or structural kidney damage for 3 months or longer. In veterinary medicine, CKD is a common disease in older cats that impacts their quality of life (QoL) and longevity …”

Section: Introductionmentioning

confidence: 99%

A Double‐blind, Placebo‐controlled, Multicenter, Prospective, Randomized Study of Beraprost Sodium Treatment for Cats with Chronic Kidney Disease

Takenaka¹,

Iio

Sato

et al. 2017

Veterinary Internal Medicne

View full text Add to dashboard Cite

show abstract

“…Moreover, the International Society of Feline Medicine consensus guidelines for the management of cats with CKD were followed (Sparkes et al. ).…”

Section: Methodsmentioning

confidence: 99%

“…Although early diagnosis of CKD is considered an important factor for positive prognosis, serum creatinine concentration and urine specific gravity assessment at 1–2 years of age and at the beginning of each year from 5 to 10 years of age should be considered to ensure a better quality and a longer life span (Grauer ; Sparkes et al. ). To date, the only pharmacological approach for CKD treatment is the management of its symptoms, for example, nausea and anorexia (Ljutic et al.…”

Section: Introductionmentioning

confidence: 99%

A nutraceutical diet based onLespedeza spp.,Vaccinium macrocarponandTaraxacum officinaleimproves spontaneous feline chronic kidney disease

Cerbo

Iannitti²,

Guidetti³

et al. 2018

Physiol Rep

View full text Add to dashboard Cite

Chronic kidney disease is characterized by structural and/or functional impairment of one or both kidneys persisting for more than 3 months. In cats, chronic kidney disease can frequently occur in animals aged over 9 years with an incidence of approximately 10%. Thirty‐four client‐owned, neutered cats, suffering from stage II‐III chronic kidney disease and diagnosed according to the International Renal Interest Society guidelines were randomly assigned to receive either a control diet (n = 17) or a nutraceutical diet (ND; n = 17) for 90 days. Both diets were commercialized for management of CKD symptoms. The diets were identical except that the ND contained tablets that consisted of 60–80% hydrolysed proteins, 20–40% minerals and active substances, that are, Lespedeza spp. 0.0588%, Vaccinium macrocarpom 0.0371%, and Taraxacum officinale 0.0231%. No adverse effects were reported during this study. Both diets resulted in an improvement in CKD symptoms. After a 90‐day evaluation, creatinine, blood urea nitrogen, total proteins, and aspartate aminotransferase significantly decreased in cats that received the ND. A significant decrease was also observed in urine turbidity score, color score, and total proteins in cats that received the ND. We have found that a ND based on Lespedeza spp., Vaccinium macrocarpon, and Taraxacum officinale improves key indicators of renal failure in cats affected by chronic kidney disease.

show abstract

“…Some clinicians advocate treating borderline proteinuric cats (UPC 0.2 to 0.4) on the basis that survival times in these cats are reduced compared to non-proteinuric CKD cats (UPC <0.2) and this is considered logical by the panel responsible for the recently published International Society of Feline Medicine (ISFM) consensus guidelines on diagnosis and management of CKD (Sparkes and others 2016). ACEI and ARBs should only be used in clinically stable, normally hydrated cats.…”

Section: What Aspects Of Management Should Be Considered In All Patiementioning

confidence: 99%

Management and treatment of chronic kidney disease in cats

Caney

2016

In Practice

Self Cite

View full text Add to dashboard Cite

Making a diagnosis of chronic kidney disease (CKD) in cats marks the start of a new and complex journey to provide optimal treatment for the patient. A successful outcome depends on attention to detail and a good working relationship with the carer and patient. If it is possible to institute good treatment measures, many patients with CKD survive for several years following diagnosis, with an excellent quality of life.

show abstract

ISFM Consensus Guidelines on the Diagnosis and Management of Feline Chronic Kidney Disease

Cited by 126 publications

References 192 publications

A Double‐blind, Placebo‐controlled, Multicenter, Prospective, Randomized Study of Beraprost Sodium Treatment for Cats with Chronic Kidney Disease

A Double‐blind, Placebo‐controlled, Multicenter, Prospective, Randomized Study of Beraprost Sodium Treatment for Cats with Chronic Kidney Disease

A nutraceutical diet based onLespedeza spp.,Vaccinium macrocarponandTaraxacum officinaleimproves spontaneous feline chronic kidney disease

Management and treatment of chronic kidney disease in cats

Contact Info

Product

Resources

About